International regulators and WHO call for wider public access to clinical data
The ICMRA and WHO are urging pharmaceutical companies to provide wide access to clinical data for new medicines and vaccines, without redaction of confidential information, to ensure results of research are accessible to all those involved in healthcare decision-making.
Source:
International Coalition of Medicines Regulatory Authorities
SPS commentary:
In the joint statement, they stress that systematic transparency can increase trust in regulatory decision-making, reassure the public about data integrity and can stimulate research and development, which could have a positive impact on vaccine confidence.